Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotypeFollowing recent approvals in the EU and China, the US approval is ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD         Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) ...

giving patients living with this devastating disease the chance to look forward to the potential of improved breathing and a life with fewer exacerbations,” Sanofi CEO Paul Hudson said in a statement.

As private equity firms reportedly place their bids, Sanofi may soon follow in the footsteps of GSK and Johnson & Johnson ...

Amgen's immunology drug results —The Novo Nordisk Senate hearing —Sanofi's soul-searching Read on to learn more.

Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...

This case stems from pharmaceutical industry's contention and awaits further merit-based proceedings. Sanofi CEO Paul Hudson ...

This summary covers various health news briefs including AstraZeneca's breast cancer drug trial results, a bird flu case in ...

Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...

Sanofi Chief Executive Paul Hudson said on Monday that the company has not made a final decision yet on how it plans to split ...